Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.

Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, Floege J, Fliser D, Heine GH.

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1049-58. doi: 10.2215/CJN.07870713. Epub 2014 Mar 27.

2.

Fibroblast growth factor-23 and cardiovascular events in CKD.

Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2014 Feb;25(2):349-60. doi: 10.1681/ASN.2013050465. Epub 2013 Oct 24.

3.

Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease.

Seiler S, Wen M, Roth HJ, Fehrenz M, Flügge F, Herath E, Weihrauch A, Fliser D, Heine GH.

Kidney Int. 2013 Jan;83(1):121-8. doi: 10.1038/ki.2012.288. Epub 2012 Aug 15.

PMID:
22895520
4.

Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).

Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG.

J Am Coll Cardiol. 2012 Jul 17;60(3):200-7. doi: 10.1016/j.jacc.2012.03.040. Epub 2012 Jun 13.

5.

[Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].

Milovanova LIu, Milovanov IuS, Kudriavtseva DV, Markina MM, Milovanova SIu, Kozlovskaia LV, Lebedeva MV, Beketov VD, Moiseev SV, Mukhin NA, Fomin VV, Svistunov AA.

Ter Arkh. 2015;87(6):10-6. Russian.

PMID:
26281189
6.

Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study.

Deo R, Katz R, de Boer IH, Sotoodehnia N, Kestenbaum B, Mukamal KJ, Chonchol M, Sarnak MJ, Siscovick D, Shlipak MG, Ix JH.

Am J Kidney Dis. 2015 Jul;66(1):40-6. doi: 10.1053/j.ajkd.2014.10.025. Epub 2015 Jan 5.

7.

Circulating α-klotho levels in CKD and relationship to progression.

Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, Kim CH, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH.

Am J Kidney Dis. 2013 Jun;61(6):899-909. doi: 10.1053/j.ajkd.2013.01.024. Epub 2013 Mar 27.

PMID:
23540260
8.

[New markers of cardio-renal links in chronic kidney disease].

Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.

Ter Arkh. 2013;85(6):17-24. Russian.

PMID:
23866594
9.

Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.

Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE.

Clin J Am Soc Nephrol. 2013 May;8(5):781-6. doi: 10.2215/CJN.09570912. Epub 2013 Jan 18.

10.

Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients.

Buiten MS, de Bie MK, Bouma-de Krijger A, van Dam B, Dekker FW, Jukema JW, Rabelink TJ, Rotmans JI.

BMC Nephrol. 2014 Dec 11;15:197. doi: 10.1186/1471-2369-15-197.

11.

Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.

Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, Hostetter T, Jaar B, Lora CM, Nessel L, Ojo A, Scialla J, Steigerwalt S, Teal V, Wolf M, Rahman M; CRIC Investigators.

Am J Kidney Dis. 2013 Oct;62(4):670-8. doi: 10.1053/j.ajkd.2013.01.017. Epub 2013 Mar 13.

12.

Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.

Lutsey PL, Alonso A, Selvin E, Pankow JS, Michos ED, Agarwal SK, Loehr LR, Eckfeldt JH, Coresh J.

J Am Heart Assoc. 2014 Jun 10;3(3):e000936. doi: 10.1161/JAHA.114.000936.

13.

Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.

Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, Lima JA, Polak JF, Blondon M, Ruzinski J, Rock D, de Boer IH.

Circ Heart Fail. 2014 May;7(3):409-17. doi: 10.1161/CIRCHEARTFAILURE.113.000952. Epub 2014 Mar 25.

14.

Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.

Matsui M, Uemura S, Takeda Y, Samejima K, Matsumoto T, Hasegawa A, Tsushima H, Hoshino E, Ueda T, Morimoto K, Okamoto K, Okada S, Onoue K, Okayama S, Kawata H, Kawakami R, Maruyama N, Akai Y, Iwano M, Shiiki H, Saito Y; NARA-CKD Investigators.

J Am Soc Nephrol. 2015 Nov;26(11):2871-81. doi: 10.1681/ASN.2014080772. Epub 2015 Mar 18.

PMID:
25788536
15.

[MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].

Milovanova LY, Kozlovskaya LV, Markina MM, Milovanova SY, Borisov AA, Mukhin NA, Fomin VV, Moiseev SV.

Klin Med (Mosk). 2015;93(12):32-8. Russian.

PMID:
27149811
16.

Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.

Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J, Lemaire S, Kautzner J, Jarolim P.

JACC Heart Fail. 2015 Oct;3(10):829-39. doi: 10.1016/j.jchf.2015.05.012.

PMID:
26450001
17.

[Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].

Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.

Ter Arkh. 2014;86(4):36-44. Russian.

PMID:
24864466
18.

Plasma ceruloplasmin, a regulator of nitric oxide activity, and incident cardiovascular risk in patients with CKD.

Kennedy DJ, Fan Y, Wu Y, Pepoy M, Hazen SL, Tang WH.

Clin J Am Soc Nephrol. 2014 Mar;9(3):462-7. doi: 10.2215/CJN.07720713. Epub 2013 Dec 5.

19.

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group.

JAMA. 2011 Jun 15;305(23):2432-9. doi: 10.1001/jama.2011.826.

20.

Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):29-38. doi: 10.2215/CJN.06190614. Epub 2014 Oct 24.

Items per page

Supplemental Content

Write to the Help Desk